A detailed history of Amalgamated Bank transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Amalgamated Bank holds 3,907 shares of SMMT stock, worth $28,286. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,907
Previous 16,405 76.18%
Holding current value
$28,286
Previous $43,000 62.79%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$2.55 - $5.07 $31,869 - $63,364
-12,498 Reduced 76.18%
3,907 $16,000
Q4 2023

Feb 06, 2024

SELL
$1.67 - $2.83 $1,942 - $3,291
-1,163 Reduced 6.62%
16,405 $43,000
Q2 2023

Aug 11, 2023

BUY
$1.32 - $2.81 $23,189 - $49,366
17,568 New
17,568 $44,000
Q2 2022

Aug 15, 2022

SELL
$0.92 - $2.38 $3,947 - $10,212
-4,291 Closed
0 $0
Q1 2022

Jun 30, 2022

BUY
$2.0 - $3.45 $8,582 - $14,803
4,291 New
4,291 $11,000

Others Institutions Holding SMMT

About Summit Therapeutics Inc.


  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $1.46B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.